Novant Health, an integrated network of physician clinics, outpatient facilities and hospitals in Virginia, North and South Carolina and Georgia, revealed on Monday the appointment of Ann Caulkins as its senior vice president as well as president of its Novant Health Foundation.
Based in Winston-Salem, North Carolina, Caulkins will design and implement plans for sustainable and integrated philanthropy across all its markets, increase the profile of the foundation within its communities, with focus on infants and children, cancer, heart and vascular, stroke and neuroscience as well as research and education.
Most recently, Caulkins has served as the president and publisher of The Charlotte Observer for 12 years.
Previously, Caulkins was the president and publisher of The State newspaper in Columbia, South Carolina, advertising director and senior vice president of sales and marketing at The Herald-Leader in Lexington, Kentucky as well as part of the Fort Worth Star-Telegram in Fort Worth, Texas at the start of her newspaper career.
Caulkins is currently a member of the boards of CrossRoads Charlotte, The Fletcher School and the Charlotte Mecklenburg Library Foundation, as well as a member of the Women's Impact Fund, International Women's Forum, Women Executives and the National Association of Corporate Directors.
Earlier, Caulkins was a member of the Charlotte Chamber of Commerce board, the Charlotte Regional Partnership board, the Queens University School of Communication Advisory Board, the Charlotte Country Day board, the University of North Carolina at Chapel Hill's School of Media and Journalism board of advisors, the Columbia Urban League board of directors and the South Carolina Palmetto Business Forum as well as board chair of the Levine Museum of the New South.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval